A couple months ahead of its PDUFA data, Bristol Myers rolls out long-term data for mavacamten

[cafead]

via It’s almost time for the FDA to make a decision on mavacamten, the myosin inhibitor at the center of Bristol Myers Squibb’s $13 billion MyoKardia buyout. With a Jan. 28 PDUFA date looming, the pharma giant is now taking the wraps off some long-term data it hopes will bolster the drug’s case for approval.

article source